Viatris reports strong second quarter results

Pittsburgh, aug. 9, 2021 /prnewswire/ --  reports second quarter 2021 financial results - total revenues of $4.58 billion, u.s. gaap net loss of $279 million, adjusted ebitda of $1.68 billion, u.s. gaap net cash provided by operating activities of $559 million, free cash flow of $470 million updates 2021 financial guidance (1) - raises total revenues guidance range to $17.5 billion to $17.9 billion from $17.2 billion to $17.8 billion, raises adjusted ebitda guidance range to $6.15 billion to $6.45 billion from $6.0 billion to $6.4 billion, raises free cash flow guidance range to $2.2 billion to $2.4 billion from $2.0 billion to $2.3 billion announces board of directors declares quarterly dividend of eleven cents ($0.11) per share pays down $1.15 billion of debt in first half of 2021 receives historic approval for first interchangeable biosimilar in the u.s. for semglee® for the treatment of diabetes in july (substitutable for the reference product, lantus®) (1) viatris is not providing forward-looking guidance for u.s. gaap net (loss) earnings or a quantitative reconciliation of its 2021 adjusted ebitda guidance. u.s. gaap net cash provided by operating activities for 2021 is estimated to be between $2.80 billion and $2.95 billion.
VTRS Ratings Summary
VTRS Quant Ranking